8-K: Altimmune's Pemvidutide Shows Positive Results in AUD Trial

Altimmune announced positive topline results from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder, meeting primary and key secondary endpoints.

Summary

• Altimmune announced positive topline results from the RECLAIM Phase 2 trial evaluating pemvidutide (2.4 mg dose) in patients with moderate to severe alcohol use disorder (AUD).
• The trial met its primary endpoint, demonstrating a statistically significant reduction in heavy drinking days (HDD) per week compared to placebo.
• Key secondary endpoints were also met, including a two-level reduction in World Health Organization (WHO) Risk Drinking Levels and achieving zero HDD, both recognized by the FDA as registrational endpoints.
• A statistically significant reduction in phosphatidyl ethanol (PEth) levels, an objective biomarker of alcohol intake, was also observed.
• Pemvidutide showed a generally favorable safety and tolerability profile, with the majority of adverse events being mild to moderate.
• The company plans to request an End-of-Phase 2 meeting with the FDA to discuss the path forward for pemvidutide in AUD.
• Pemvidutide also demonstrated a statistically significant reduction in body weight, with a placebo-adjusted difference of 9.1% at 24 weeks.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, with the trial meeting its primary and key secondary endpoints, indicating significant progress towards potential regulatory approval and commercialization.

Positives

• The primary endpoint of a statistically significant reduction in heavy drinking days per week versus placebo was met (p=0.0014).
• Key secondary endpoints, including two FDA registrational endpoints (two-level reduction in WHO Risk Drinking Levels and zero heavy drinking days), were statistically significant.
• A statistically significant reduction in serum PEth levels was observed (p<0.0001).
• A statistically significant change in the percent of days with abstinence versus placebo was noted (p=0.0075).
• Pemvidutide demonstrated a statistically significant reduction in body weight (9.1% placebo-adjusted difference at 24 weeks, p<0.0001).
• A generally favorable safety and tolerability profile was observed.
• Nearly two-thirds of patients treated with pemvidutide achieved a two-level reduction in their WHO-RDL.

Negatives

• Nausea was reported in 44% of patients on pemvidutide compared to 24% on placebo.
• Vomiting occurred in 18% of patients on pemvidutide versus 6% on placebo.
• Diarrhea was reported in 20% of patients on pemvidutide compared to 10% on placebo.
• Constipation occurred in 26% of patients on pemvidutide versus 6% on placebo.
• Five patients (10%) on pemvidutide discontinued treatment due to study drug-related adverse events.
• One serious adverse event (hyponatremia) in the pemvidutide arm was deemed possibly related to the treatment drug.

Risks

• The company cautions that forward-looking statements are subject to numerous assumptions, risks, and uncertainties.
• Potential risks include delays in regulatory review, manufacturing and supply chain interruptions, and adverse effects on healthcare systems.
• Patient baseline characteristics may vary and impact the success of future trials.
• The reliability of study results regarding human safety and possible adverse effects is a consideration.
• The company's ability to manufacture clinical trial materials on anticipated timelines is a risk.
• There is a risk that the FDA may not agree with the company's proposed development and regulatory strategy for pemvidutide in AUD.
• Results from the RECLAIM trial may not be predictive of results in future trials.
• The company requires substantial additional capital, which may not be available on acceptable terms.

Future Outlook

Altimmune plans to request an End-of-Phase 2 meeting with the FDA to discuss the regulatory path for pemvidutide in AUD. Results from the RECLAIM trial will be submitted for presentation at a medical conference and publication in a peer-reviewed journal. The company also plans to initiate the PERFORMA Phase 3 trial in MASH in Q3 2026.

Management Comments

• "We are extremely encouraged by these compelling topline results, which showed a highly significant reduction in heavy drinking days and nearly two-thirds of patients treated with pemvidutide achieving a two-level reduction in their WHO-RDL, a clinically meaningful outcome for these patients."
• "These data reflect pemvidutide's strong and consistent efficacy across important measures of drinking behavior, together with a generally favorable tolerability profile in this difficult-to-treat disorder."
• "Given the known detrimental effects of alcohol on the liver, the liver-directed impact of glucagon in pemvidutide may provide further benefit in the treatment of AUD over GLP-1 alone, underscoring pemvidutide's promising potential differentiation."
• "These results provide a consistent picture of treatment benefit on self-reported drinking outcomes, supported by objective PEth biomarker evidence."
• "These data underscore the potential for pemvidutide to address multiple dimensions of alcohol use disorder by supporting abstinence and reducing heavy drinking, findings that build on prior evidence of its activity in the liver."
• "These top-line data strengthen our confidence in pemvidutide's differentiation and its potential to benefit people living with MASH, AUD and ALD, who currently have limited treatment options."
• "These results represent yet another important milestone for Altimmune as we continue to execute on our goal to bring pemvidutide to patients with serious liver diseases while creating value for shareholders."

Industry Context

StockSavvy.ai notes that the positive results for pemvidutide in AUD align with the growing focus on novel therapeutic approaches for substance use disorders. The dual glucagon/GLP-1 mechanism offers a potential advantage by addressing both metabolic and behavioral aspects of AUD, while also potentially benefiting liver health, a common comorbidity. The unmet need for effective AUD treatments remains high, with current options having limited efficacy.

Comparison to Industry Standards

• The trial met its primary endpoint with a p-value of 0.0014, indicating a high degree of statistical significance.
• The achievement of two FDA registrational endpoints (two-level WHO-RDL reduction and zero HDD) is a critical benchmark for advancing to later-stage trials.
• The observed reduction in PEth levels, a direct biomarker of alcohol consumption, provides objective validation of the treatment effect, which is a high standard in AUD research.
• The 9.1% placebo-adjusted body weight reduction is consistent with the known effects of GLP-1 agonists and adds a metabolic benefit often seen in patients with AUD.

Stakeholder Impact

• Shareholders: Positive results may lead to increased investor confidence and potential stock price appreciation.
• Patients: Potential for a new, more effective treatment option for moderate to severe alcohol use disorder.
• Healthcare Providers: May offer a new therapeutic tool with a potentially favorable profile for managing AUD.
• FDA: The results will be reviewed to determine the path forward for potential drug approval.

Next Steps

• Request an End-of-Phase 2 meeting with the FDA.
• Submit RECLAIM trial results for presentation at a medical conference.
• Submit RECLAIM trial results for publication in a peer-reviewed journal.
• Initiate the PERFORMA Phase 3 trial in MASH in Q3 2026.

Key Dates

Recommendation

While the results are positive and meet key endpoints, further clinical development and regulatory review are required. The company also faces significant capital needs. Therefore, a 'hold' recommendation is appropriate pending further de-risking events and clarity on future funding and regulatory pathways.

Keywords

Alcohol Use Disorder, Pemvidutide, Phase 2 Trial, Glucagon/GLP-1 Dual Receptor Agonist, Heavy Drinking Days, WHO Risk Drinking Levels, Phosphatidylethanol, Biopharmaceutical